2020
DOI: 10.4084/mjhid.2020.006
|View full text |Cite
|
Sign up to set email alerts
|

Concise Review on the Frequency, Major Risk Factors and Surveillance of Hepatocellular Carcinoma (Hcc) in Β-Thalassemias: Past, Present and Future Perspectives

Abstract: Due to the recent alarming increase in the incidence of hepatocellular carcinoma (HCC) in thalassemias, the aim of the present report is to review briefly the frequency, the major risk factors and the surveillance of HCC in β-thalassemias. Over the past 33 years, 153 cases of HCC were reported in patients with thalassemia, mainly in Italy, and Greece. Among HCV-infected patients additional factors promoting development of  HCC, included: advanced age, male sex, chronic hepatitis B (CHB) coinfection, and iron o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
16
0
2

Year Published

2020
2020
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 21 publications
(19 citation statements)
references
References 100 publications
(157 reference statements)
1
16
0
2
Order By: Relevance
“…Furthermore, HCV infection leads to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). 37 Until couple of years ago, the recommended therapy for HCV treatment consisted of chelation therapy along with pegylated-interferon alpha plus ribavirin, a therapy with significant side effects. 38 More recently, the use of Direct-acting Antiviral Agents (DAAs) gave a breakthrough and demonstrated to be appropriate in HCV management in patients with thalassemia disease for whom previous regimens gave restrictions.…”
Section: Discussionmentioning
confidence: 99%
“…Furthermore, HCV infection leads to liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). 37 Until couple of years ago, the recommended therapy for HCV treatment consisted of chelation therapy along with pegylated-interferon alpha plus ribavirin, a therapy with significant side effects. 38 More recently, the use of Direct-acting Antiviral Agents (DAAs) gave a breakthrough and demonstrated to be appropriate in HCV management in patients with thalassemia disease for whom previous regimens gave restrictions.…”
Section: Discussionmentioning
confidence: 99%
“…The incidence of HCC in patients with TM has been calculated as 3.5%. Data from a prospective study with 105 adults with TDT reveal a 2% incidence of HCC during a one-year observation period [16] . Furthermore, preliminary data regarding HCC survey from 1327 thalassemic patients, aged > 30 years from 13 centers, enrolled in the International Network of Clinicians for Endocrinopathies in Thalassemia and Adolescent Medicine (ICET-A), reveal a prevalence of 1.66% in TDT patients and 1.96% in non-TDT patients [17] [Table 1].…”
Section: Hcc In Tdt Epidemiologymentioning
confidence: 99%
“…Beta-thalassemia patients with HCC present relevant co-morbidities: hypogonadism (55%), myocardiopathy (52%), hypothyroidism (42%), osteoporosis (31%), diabetes (31%) and chronic renal failure (4%) [79]. This needs to be taken into account when planning surgical resection.…”
Section: Mrimentioning
confidence: 99%